Jump to content

Repligen

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ground Zero (talk | contribs) at 02:17, 21 March 2016 (use verb tenses instead of adverbs to express time). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Repligen Corporation
Company typePublic company
Nasdaq: RGEN
IndustryPharmaceutical industry
Founded1981
FounderAlexander Rich and Paul Schimmel
Headquarters
Waltham, Massachusetts
,
United States
Key people
Walter C. Herlihy (President, CEO)
ProductsMaterials used in the manufacture of biological drugs
RevenueIncreaseUS$68 million
IncreaseUS$23 million
Total assetsIncreaseUS$119 million
Total equityIncreaseUS$104 million
Number of employees
116 (2014)
Websitewww.repligen.com

Repligen (RepliGen in the company's logo)[1] is an American company devoted to the development and production of materials used in the manufacture of biological drugs.2014 The company is based in Waltham, Massachusetts,2014 and incorporated in Delaware in 1981.[2] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN.[3] As of February 2014, Repligen employed 116 people, about 50% of these based in Sweden.[4]

Business model

Prior to 2012, Repligen maintained dual capabilities in the development of pharmaceutical therapeutics (drug discovery and development) and the development of materials supporting biological drug manufacture (bioprocessing business).[5] A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures.[6] In the period of 2010 to 2013, the majority of sales by the company were concentrated in the single Protein A product line.[7]

Sales and revenue

Repligen employs a direct sales model to users of its products in the United States, with some sales through intermediaries in "certain foreign markets".[8] More than 80% of sales have been to customers in the United States and Sweden during the 2010-2013 period.[8] Long-term supply agreements have been established with major customers of the Protein A products, agreements which expire between 2016 and 2021 barring re-negotiation.[9]

As a result of royalty-generating out-licensing, royalty revenue from Bristol-Myers Squibb has been in the 27% to 37% range as a proportion of total revenue during the 2010-2013 period; in comparison to revenue from sales, the largest customer accounted for 35% to 45% of revenue during the same period.[4]

As a consequence of current operations, about one-third each of revenue and cost and expenses are denominated in Swedish krona currency, the remaining two-thirds denominated in United States dollars; this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates.[10]

Intellectual property

The company's Protein A-related offerings are supported by proprietary technology, trade secrets and patent filings.[4] One patent was granted in April 2010 and has been extended so that it remains in effect until 2028.[4],[11] Patents are pending on elements of the OPUS chromatography product line,[4] and enabling technology has been licensed from BioFlash Partners.[7] Repligen retains an exclusive license to intellectual property owned by the University of Michigan in relation to the Orencia product divested to Bristol-Myers Squibb.[8],[12]

Facilities

Repligen's company headquarters are housed together with its manufacturing facility in Waltham, Massachusetts.[13]

Repligen maintains manufacturing facilities in Waltham, Massachusetts and Lund, Sweden.[2] Growth factor products and the native form of Protein A are manufactured in Sweden; recombinant forms of Protein A are manufactured in both the United States and Sweden; assembly of the OPUS chromatography product line is done in the United States.[9]

The lease on the main Waltham facility extends through 2023.[13] A second, smaller Waltham facility was leased through the end of 2012 and is now rented on a monthly basis.[14] In Lund, four buildings are under lease, three expiring in mid-2017 and the fourth extending to late 2019.[14]

Corporate history and governance

Alexander Rich was a co-founder of Repligen; in 2014 at the age of 87, Dr. Rich is "Chairman Emeritus".[15]of Repligen's Board of Directors. Dr. Rich had been a member of the Board since 1981.[16] Paul Schimmel is also a co-founder of Repligen; in 2014 at the age of 74, he is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He used to be the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT.

As of 2014, the company's President and Chief Executive Officer is Walter C. Herlihy.[15]

Acquisitions and in-licensing

In early 2010, Repligen licensed technology from BioFlash which it subsequently incorporated into the OPUS line of pre-packaged chromatography columns.[7]

In 2011, Repligen acquired bioproduction assets from Novozymes for US$26,400,000, which doubled the company's bioprocessing capabilities.[5]

Divestments and out-licensing

In 2008, an agreement was struck to divest certain intellectual property rights to Bristol-Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of 2013.[5]

At the end of 2012, Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG3039, to Pfizer.[5] This divestment included licensing rights to two patents to Pfizer.[9],[17],[18]

At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$2,000,000 and future milestone and royalty payments.[2],[19]

Terminations and moth-balling

Development of an imaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by the USFDA for additional safety and efficacy data beyond that provided in a New Drug Application (NDA) submission; a Marketing Authorization Application had been submitted in parallel to the EMA.[2]

Financial history

Financials from 2013 10-K[20][21]
2010 2011 2012 2013
Revenue 20,971 27,291 62,267 68,169
Operating Income (5,767) (374) 11,083 22,873
Net Income (40,064) (43) 14,156 16,093
Total Assets 71,420 72,294 97,010 118,645
Total Equity 66,120 67,087 84,125 103,886

Products and services

Repligen is a major supplier of Protein A, both native and recombinant forms, to the pharmaceutical industry.[5] In 2010-2013, Protein A accounted for the majority of the company's product sales.[7] The company also provides growth factors to increase the productivity of cell-based bioproduction and a line (OPUS) of chromatography columns scaled to manufacture of product for testing in clinical trials.[5]

The OPUS product line contains a range of column sizes, the size and composition of which are dependent upon customer requirements, thus the full name of "Open Platform, User Specified".[6] The smaller sizes of columns depend upon proprietary technology licensed from BioFlash Partners, while the larger sizes are based on Repligen-developed proprietary technology.[7]

Notes

  1. ^ As of 2014, the company's logo image can be found at http://www.repligen.com/sites/all/themes/repligen/images/logo-corporate.gif .
  2. ^ a b c d Repligen 2013 10-K 2014, p. 2.
  3. ^ Nasdaq: RGEN
  4. ^ a b c d e Repligen 2013 10-K 2014, p. 6.
  5. ^ a b c d e f Repligen 2013 10-K 2014, p. 1.
  6. ^ a b Repligen 2013 10-K 2014, p. 4.
  7. ^ a b c d e Repligen 2013 10-K 2014, p. 3.
  8. ^ a b c Repligen 2013 10-K 2014, p. 5.
  9. ^ a b c Repligen 2013 10-K 2014, p. 7.
  10. ^ Repligen 2013 10-K 2014, p. 18.
  11. ^ B2 US 7691608 B2  "Nucleic Acids Encoding Recombinant Protein A"
  12. ^ US 6685941  "Methods of treating autoimmune disease via CTLA-4Ig"
  13. ^ a b Repligen 2013 10-K 2014, p. 19.
  14. ^ a b Repligen 2013 10-K 2014, p. 20.
  15. ^ a b Motley Fool 2014.
  16. ^ Forbes 2014.
  17. ^ US 7888366  "2,4-diaminoquinazolines for spinal muscular atrophy"
  18. ^ US 7985755  "2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY"
  19. ^ Gen. Eng. Biotechnol. News 2014.
  20. ^ Repligen 2013 10-K 2014, p. 23.
  21. ^ Values are presented in thousands of US dollars (6,100 = 6.1 million); negative values appear in parentheses.

References

  • Forbes (2014). "Alexander Rich". Profiles. Forbes. Archived from the original on 15 March 2014. Retrieved 15 March 2014. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  • Gen. Eng. Biotechnol. News (February 15, 2014). "BioMarin Nabs Repligen's HDACi Compound Library". News: Discovery & Development. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. p. 14. {{cite news}}: Invalid |ref=harv (help)
  • International New York Times (2014). "Repligen Corporation". Business Day. International New York Times. Company Information. Archived from the original on 15 March 2014. Retrieved 15 March 2014. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  • Motley Fool (2014). "Repligen Corp Key Executives RGEN". The Motley Fool. Archived from the original on 15 March 2014. Retrieved 15 March 2014. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  • "Repligen Corporation, Form 10-K, 2013", SEC Documents, Form 10-K, Repligen, 2014, Commission File Number 000-14656, retrieved 16 March 2014
  • Street Insider (19 September 2011). "Repligen (RGEN) Replaces Board Member Alex Rich with Alfred Goldberg". Street Insider. Archived from the original on 15 March 2014. Retrieved 15 March 2014. {{cite news}}: Invalid |ref=harv (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Repligen&oldid=711134439"